OBSErve Germany was the first observational study of belimumab as add-on treatment for systemic lupus erythematosus (SLE) in routine clinical care in Germany, retrospectively collecting data from 102 SLE patients, 6 months before and after belimumab initiation. Most patients had moderate or severe SLE and several SLE manifestations. After 6 months of belimumab treatment, 78% of patients showed an improvement in overall disease activity of at least 20% in their physician's judgment and for 42% of patients the improvement was at least 50%. Similar results were observed for the most common manifestations: arthritis, fatigue, rash, alopecia, increased anti-dsDNA antibody levels, and low complement. The SLE Disease Activity Index (SLEDAI/SELENA-SLEDAI) decreased from 10.6 to 5.6 (n = 65), with other indices also showing Rheumatol Ther (2016) 3:271-290 DOI 10.1007 improvement. A notable dose reduction was seen for concomitant oral corticosteroids, from 13.7 to 7.6 mg/day overall (n = 91), and from 17.5 to 8.6 mg/day in patients with a high corticosteroid dose at belimumab initiation (C7.5 mg; n = 63). Six patients discontinued belimumab therapy within 6 months. Overall, belimumab showed promising results for SLE patients in real-world settings. After 6 months of belimumab treatment, disease activity and corticosteroid use were reduced. The discontinuation rate was low and belimumab appeared to be well tolerated.
INTRODUCTION
Systemic lupus erythematosus (SLE) is an autoimmune disease with heterogeneous morbidities, involving the skin, joints, kidneys, or central nervous system. The clinical course is characterized by chronic remitting and relapsing phases which usually requires life-long medication to manage disease activity. Standard medications for SLE include oral corticosteroids, antimalarials, cytotoxic agents, non-steroidal anti-inflammatory drugs (NSAIDs), and immunomodulators/immunosuppressors, some of which can lead to severe side effects, especially at higher doses [1] [2] [3] [4] [5] [6] [7] . Potentially severe complications of SLE include lupus nephritis and central nervous system vasculitis, both of which require long-term treatment with high doses of corticosteroids and/or cyclophosphamide and tend to relapse [1, 8] .
The combination of SLE manifestations and side effects of long-term medication use can severely impact on the patients' quality of life and ability to work. However, advances in therapy and management have increased life expectancy and quality of life for SLE patients [9, 10] .
New types of therapies include biologicals [11, 12] , e.g., the BLyS (B lymphocyte stimulator) inhibitor belimumab (trade name Benlysta Ò ), a human monoclonal IgG1k
antibody that is indicated for adult autoantibody-positive SLE patients that require an add-on to other SLE medications due to a persisting high degree of disease activity despite standard therapy, e.g., in cases with ineffectiveness or intolerability of other medications [13] . Belimumab received market authorization for Europe and the USA in 2011, after safety and efficacy were confirmed in two randomized, placebo-controlled clinical trials [14] [15] [16] [17] [18] , subsequently followed by an ongoing continuation study [19] . At this stage, it is essential to evaluate how the results of these studies translate into the clinical reality of managing and treating SLE patients.
BLyS is an essential B cell survival factor acting by binding to specific B cell surface receptors. In SLE, an excess concentration of BLyS inhibits the physiological apoptosis of autoreactive B cells and promotes their pathological differentiation into autoantibody-producing plasma cells. Belimumab acts by capturing and inhibiting soluble BLyS before it binds to its receptors, thus indirectly inhibiting the survival and differentiation of autoreactive B cells, as well as the subsequent production of autoantibodies by plasma cells [20, 21] . Belimumab is a long-term treatment administered as an intravenous infusion, with the initial three doses given every 2 weeks (week 0, 2, 4) followed by 4-weekly administrations. Clinical response has been described as early as 8 weeks [22] . However, generally patients should be treated for 6 months before a decision about treatment discontinuation due to lack of response is taken [13] . Patients with high disease activity levels despite standard therapy have been shown to benefit most from belimumab treatment, especially regarding clinical disease activity (e.g., as measured by validated scores), corticosteroid dependence, and laboratory markers such as autoantibody-positivity or low complement levels [16] . OBSErve is a multinational study programme with results having been reported from the USA and Spain so far [23, 24] . The present study, OBSErve Germany (Evaluation 
METHODS

Study Design
OBSErve Germany was a retrospective, 
Study Population
OBSErve Germany was sponsored by GSK who contributed their knowledge about sites with experience in prescribing belimumab to be contacted with a feasibility questionnaire.
According to the predefined eligibility criteria, the study sample included clinical sites which had at least 5 years of experience in treating SLE patients and at least 6 months experience in the usage of belimumab for SLE. At the start of the study the participating physicians were required to be managing at least ten SLE patients at the time and to have initiated belimumab in at least two patients as part of routine care, with at least one of them still receiving belimumab at the time.
Patients included in the documentation had to be at least 18 years old and belimumab-naïve with a confirmed diagnosis of SLE. For these patients, treatment with belimumab had to be initiated as part of routine care at least 6 months before inclusion into the study, ensuring a purely retrospective observation and documentation of the first 6 months of the treatment. All eligible patients had to be included at each site, also if they discontinued belimumab therapy within the initial 6 months, in order to also obtain insight into the [26] . Therefore, the physicians' judgment scale, used identically across the whole OBSErve study programme, aimed to obtain a subjective clinical rating.
Additionally, disease assessments using Physician Global Assessment Scales and Patient Global Assessment Scales were collected where available. The physicians who documented results from these scales used their internal rating system and the results were then converted to a scale ranging from 0 to 100, based on the ranges provided by the physicians.
Data collection was performed using an electronic data capture system (EDC).
Automatic checks were implemented in the EDC to avoid missing answers and to provide valid and plausible data entries. During the study it was discovered that data related to concomitant SLE medication were incomplete.
Thus, queries were sent out to the respective physicians to confirm and to complete the provided information.
Data Analysis
All statistical analyses were performed in a descriptive manner and were interpreted in an explorative way. Tables were created with 
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RESULTS
Baseline Characteristics of Study Sites
For this study, SLE patient data and treatment outcomes under belimumab therapy were collected retrospectively for 102 patients from 21 sites in Germany, mainly hospitals (76%).
On average (mean ± standard deviation), the physicians' experience in treating SLE patients was 15.7 ± 6.74 years (min 5, max 30 years). They were treating 72.7 ± 30.51 SLE patients (min 20, max 100 patients) at the time of data collection. Each physician, on average, was treating 5.7 ± 4.73 patients with belimumab.
Of these, 4.8 ± 2.17 patients had been receiving belimumab for at least 6 months.
The most common disease assessment tools used routinely by the study sites for SLE management were the SLEDAI (57%)/ SELENA-SLEDAI (29%), the Patient Global Assessment Scale (43%), the ECLAM (38%), and the Physician Global Assessment Scale (33%). Furthermore, the most frequent routine laboratory analyses included testing of C3 and C4 concentrations (performed by 100% of physicians), serum creatinine levels (100%), C-reactive protein levels (95%), as well as a complete blood count (95%). The majority of participating physicians (62%) stated that the patient's opinion was highly important when considering changes in the individual SLE therapy.
Patient Baseline Characteristics and Reasons for Initiating Belimumab Therapy
A total of 102 patients were included in the analysis. Most of them were female (91%) and all but one were Caucasian. The mean age of the patients was 42.5 ± 13.83 years (min 19, max 76) and the mean body mass index was 25.3 ± 6.19 kg/m 2 . The SLE-related baseline data and the co-morbidities of the patients are provided in Table 1 .
The patients' SLE disease severity before initiating belimumab treatment, i.e., at baseline, was assessed by their physician. The majority of patients had moderate (60%) or severe (25%) SLE and most (58%) had been diagnosed with SLE more than 10 years ago. The most common laboratory findings for these patients at baseline were high levels of anti-dsDNA antibodies (in 72% of patients) and below-normal levels of the complement components 3 (61%) and 4 (52%).
The number of clinical and serological manifestations of SLE varied in the study population, but for 60% of patients, four or more manifestations were documented at baseline. The most frequently documented SLE manifestations at baseline were arthritis (67% of patients), increased anti-dsDNA antibody levels (56%), low complement levels (47%), rash (40%), lupus nephritis (25%), and alopecia (25%). The most frequently listed co-morbid conditions of the patients at the start of belimumab therapy were fatigue (41%), hypertension (35%), osteoporosis (20%), and depression (12%).
The indication for belimumab was related to mucocutaneous, arthritis, serositis, and mild lupus nephritis occurring with other lupus manifestations. The most common reason for initiating belimumab therapy was ineffectiveness of the patient's previous treatment regimen (88% of patients). Further common reasons were a worsening of the patient's condition (61%) and a desire to decrease the use of corticosteroid drugs (''steroid sparing'') (40%).
SLE Disease Activity at Baseline
The following comparisons of results from baseline to 6 months later are presented for all 96 patients who completed the initial 6 months of treatment. This reflects the recommendation made by the European regulatory authority (the Hemolytic anaemia 6 6 None of these 9 9
Number of SLE manifestations at start of belimumab therapy European Medicines Agency, EMA), and laid down in the summary of product characteristics for belimumab, to initially administer belimumab for at least 6 months before evaluation of the treatment result and before any decision about continuation of the treatment [13] . Six patients discontinued the study before this time point (see details below).
A formal tool to measure disease activity was used for 76 patients (79%), at baseline and after the initial 6 months of belimumab therapy.
Here, the physicians most frequently reported SLEDAI/SELENA-SLEDAI scores (for 65 patients; score range from 0 (no disease activity) to 105), with a mean score of 10.6 ± 6.09 at baseline (min 0, max 28), followed by the ECLAM (for 19 patients; range from 0 (no disease activity) to 10), with a mean score of 2.9 ± 2.03 (min 0, max 7). The Physician Global Assessment Scale was used for 17 patients (range from 0 (no disease activity) to 100) and the mean baseline score was reported as 71.9 ± 13.56 (min 30, max 88), and the Patient Global Assessment Scale (performed for eight patients; range from 0 (no Outcomes of Belimumab Therapy After
Initial 6 Months
The patients' overall clinical response to belimumab was assessed by their physician after 6 months of treatment. For the majority of patients, improvement between 20% and 79% was documented (Fig. 1 ). An overall clinical improvement of at least 20% was observed in 78% of patients and an improvement of at least 50% in 42% of patients.
When assessing the six most common clinical and serological manifestations of SLEarthritis, increased anti-dsDNA antibody levels, low complement, fatigue, rash, and alopeciamost manifestations showed improvement after 6 months of belimumab therapy for the majority of patients, as assessed by the physicians (Fig. 2) . Notably high improvement levels were reported for a large proportion of patients with arthritis and rash, while complement levels showed the least improvement overall. Improvements were also seen in the disease activity assessments ( Table 2 ). The mean SLEDAI/SELENA-SLEDAI score decreased from 10.6 to 5.6 during the first 6 months of therapy.
Similarly, most of the other commonly used indexes, the ECLAM, the Physician Global Assessment Scale, and the Patient Global Assessment Scale all showed lower, i.e., improved scores after 6 months of belimumab therapy.
Discontinuations Before End of Initial 6 Months of Belimumab Therapy
Six patients discontinued belimumab treatment within 6 months; at the time of discontinuation they had received belimumab for an average of 64 ± 51.85 days (min 15, max 155 days).
Consequently, no results for the time point after 6 months of belimumab treatment are available for these patients and they could not be included in the analyses after 6 months presented above. The six patients had ratings of ''worse'' (four patients), ''no improvement'' (one patient) and ''\20% improvement'' (one Table 3 . A total of 91 patients who completed the 6 months' course of belimumab therapy received oral corticosteroids at the start or during this therapy and were evaluated regarding their daily corticosteroid intake. A notable dose reduction of oral corticosteroids was observed for these patients (Fig. 3) .
The mean dose of corticosteroids was 11.7 mg/day 6 months before belimumab No change (250 mg/day IV)
AE adverse event, SAE serious adverse event, SLE systemic lupus erythematosus, IV intravenous a SLE improvement from start of belimumab therapy (baseline) to time of discontinuation b Relationship to belimumab treatment, according to AE reporting form c Change in dose of concomitant corticosteroid medication from baseline to time of discontinuation therapy, 13.7 mg/day at belimumab start, and 7.6 mg/day after 6 months of treatment. A similar reduction of the mean dose was also seen when analyzing only those 63 patients who were being treated with a dose of corticosteroids of at least 7.5 mg/day at the start of belimumab treatment (Table 5) . Of these 63 patients, 29 had switched to a low dose (less than 7.5 mg/day) after 6 months of belimumab therapy. Those 32 patients who remained on a (Table 6 ). While the number of scheduled visits to the physician's practice per patient increased during belimumab therapy due to the infusions, the number of unscheduled visits was reduced overall.
DISCUSSION
The OBSErve Germany study reflects the real-world practice of treating SLE with belimumab after its approval in Germany 2011. As a result of its purely retrospective character and the methodological approach, the Data are shown for all patients who received oral corticosteroids at one of these time points and who completed the initial 6 months of belimumab therapy (N = 91), as well as for all patients who initiated belimumab treatment while taking a dose C7.5 mg/day (N = 63) or a low dose (N = 27) of oral corticosteroids a One patient initiated corticosteroid intake after start of belimumab therapy and was therefore only included in the ' 'Total' ' column, not in the subgroups by starting dose results are only descriptive for the patients included and no formal conclusions regarding the effectiveness and tolerability of belimumab can be drawn for populations other than this.
The OBSErve Germany study aimed to elucidate how belimumab is being used in routine clinical care in Germany (its initiation and discontinuation), 2 years after its marketing authorization. The patient data included in the study were sourced from 21 clinical sites with experience not only in treating SLE patients but also in prescribing belimumab. The demography of the patient population was as expected for SLE patients in Germany, including predominantly white females [27] . Most of the 102 documented patients had been living with SLE for a number of years and had moderate or severe disease. Many of them were serologically active with high levels of anti-dsDNA antibodies and below-normal levels of complement components in their blood and were suffering from several clinical SLE manifestations like arthritis, nephritis or rash, and from other co-morbid conditions such as fatigue, hypertension, and osteoporosis.
Belimumab therapy was most commonly initiated because previous treatments had been regarded as ineffective. Thus, the study population included mainly patients with a long and severe SLE history not sufficiently controlled by other medications. Reflecting this, all patients had been taking a number of other SLE medications before starting belimumab therapy and also continued taking other drugs along with belimumab, most frequently oral corticosteroids. In 26 patients a manifestation of mild lupus nephritis was present together with other manifestations. Of note, belimumab is not recommended in patients with severe acute renal involvement (serum creatinine greater than 2.5 mg/dl, proteinuria greater than 6 g/day) or acute neuropsychiatric lupus, that were not present in our cohort. Overall, the baseline characteristics showed that belimumab is being prescribed appropriately in routine care; it is indicated as an additional therapeutic measure for patients with high disease activity Table 6 Unscheduled health resources utilization documented for the SLE patients in the OBSErve Germany study during the initial 6 months of belimumab therapy, in comparison to the 6 months before start of belimumab treatment (N = 96) higher doses (at least 7.5 mg/day; [30] ) makes any corticosteroid reduction to at least below this threshold one of the key therapeutic targets in SLE management [7] . After the initial 6 months of belimumab therapy, the mean dose of corticosteroids taken by the patients had decreased markedly and more than half of the patients who had entered belimumab treatment on a high dose of corticosteroids were able to change to a low dose. While the randomized clinical trials with belimumab were not designed to show a steroid-sparing effect, the OBSErve Germany results contribute to the growing set of data describing such outcomes. If the potential link between belimumab treatment and corticosteroid sparing can be proven in further clinical or observational studies, it will be highly relevant for the management of SLE patients, especially for those who do not cope well with the side effects of corticosteroids and/or who could not achieve a dose within an acceptable range before. In contrast to the corticosteroid intake, the use of other concomitant medications was not reduced in this study.
Finally, the extent of utilization of healthcare resources was evaluated for the study population. As an innovative antibody therapy, belimumab treatment is more costly than other SLE medications. However, its benefits appear to impact other healthcare resources in routine clinical care. In the OBSErve Germany study, the patients required fewer SLE-related emergency room visits and fewer SLE-related hospitalizations in the 6 months of belimumab therapy than in the 6 months before. Therefore, the effect of belimumab on the concomitant SLE medication may be of interest in further investigations covering a longer time period. Compared to the patient population in the BLISS studies [14, 15] , the patients documented in the OBSErve Germany study had a higher mean disease activity. The observations described here are highly consistent with a subgroup analysis of the BLISS patients which shows that patients with higher disease activity are the ones responding best to belimumab [16] . On the basis of these results, further SLE subgroups may be of interest for assessing the risks and benefits of belimumab treatment. For example, a large clinical trial is currently ongoing to investigate belimumab treatment outcomes specifically for adult patients with active lupus nephritis. As a result of the retrospective and observational nature of the OBSErve study, safety data were not collected in detail. However, the data on discontinuations may provide some insight into safety aspects. Six of the 102 study patients discontinued belimumab treatment within 6 months. For three of these patients, their physicians documented ''disease progression'' and ''ineffective medication'' as the reasons for withdrawing belimumab. In these patients, treatment was discontinued after 16, 35, and 68 days, respectively, i.e., within the first 10 weeks. This is a point in time where the full clinical effect of belimumab cannot yet be expected. As s result of its mode of action and supported by the clinical study results, a minimum treatment period of 6 months is recommended in the summary of product characteristics for belimumab [13] , to allow full efficacy to develop before a decision regarding further therapy is made. In the three patients described here, the constellation of their course of disease and their concomitant corticosteroid doses at least leaves some questions open, one of them being whether more patience regarding the development of the therapeutic effects could have led to different treatment results. Two of the patients discontinued because of an adverse event, one of which was an allergic reaction. This is consistent with the summary of product characteristic for belimumab, which describes that 1% of belimumab study patients are withdrawn from the treatment because of an allergic reaction [13] . For the one patient who died, no causal relationship to belimumab was suspected.
These results are consistent with the conclusion from the clinical trials that belimumab is generally well tolerated although this study did not collect safety data besides those leading to withdrawal [32] . As with other immunomodulatory drugs or antibody therapies, patient monitoring remains important, however, especially during and after the first exposures.
Overall, the effectiveness of belimumab seen in the OBSErve Germany study exceeded the expectations from the pivotal trials [14] [15] [16] with regards to the extent of clinical improvement and to its onset. Whether this is a real effect or a methodological bias due to the high hurdles to achieve the primary endpoints in clinical studies needs to be evaluated further. Very similar results have been presented for patients in Spain and in the USA (OBSErve Spain, published in an abstract [24] ; OBSErve US [23] ). Other, smaller-scale studies assessing the effectiveness of belimumab in a real-world setting have also confirmed belimumab as an option for patients not sufficiently controlled by conventional therapies [33] [34] [35] [36] [37] .
